Pharvaris N.V. (PHVS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Pharvaris N.V. (PHVS) closed at USD 29.64 on 2026-10-15, a change of +34.2 % over the past year, with a market capitalization of USD 1.95B.

Pharvaris N.V. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pharvaris N.V. key figures

Previous close

USD 29.64 (2026-10-15)

1-year change

+34.2 %

Market cap

USD 1.95B

Enterprise value

USD 1.63B

P/E ratio (trailing)

-9.07

P/E ratio (forward)

-9.11

EPS (trailing)

-3.06

EPS (forward)

-3.05

PEG ratio

n/a

Price to book

5.77

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.89

Employees

148

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pharvaris N.V. and compare it with other stocks.